Dosage Forms

Articles

The University of South Australia is working to develop needle-free vaccines for Zika, chikingunya, and peanut allergy in a collaboration with Australian biotechnology company Sementis and Enesi Pharma, a United Kingdom-based pharmaceutical company.

International Partnership Aims to Develop Needle-free Vaccines

The vaccine producer announced an expansion to its Holly Springs, NC, manufacturing facility where it will increase production of its cell-based quadrivalent influenza vaccine.

Seqirus Announces $140-Million Expansion for Vaccine Facility

The company will collaborate with GlycoBac to offer an insect cell line for the development of viral vaccines and gene therapies.

MilliporeSigma Offers Insect Platform for Viral Vaccines and Gene Therapy Development

A new investigational vaccine, LASSARAB, shows promise for use against Lassa fever and rabies.

Scientists Develop New Vaccine for Lassa Fever and Rabies

Research by Thermo Fisher Scientific and LumaCyte suggests that LumaCyte's Radiance instrument offers the ability to rapidly analyze viral vaccines to speed development and production and ensure their effectiveness.

New Analytical Instrument Could Change Vaccine Development Through Faster Viral Detection

Research from the Perelman School of Medicine at the University of Pennsylvania suggests that a universal flu vaccine that protects people against most influenza strains is one step closer to reality.

Study Finds Candidate for Universal Flu Vaccine Protects Against Multiple Strains

The Coalition for Epidemic Preparedness Innovations (CEPI) and vaccine manufacturer IDT Biologika will collaborate to develop and manufacture a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

CEPI, IDT Partner to Develop MERS Vaccine

Experts from the Partnership for Research on Ebola VACcination report on progress and uncertainties regarding a safe and effective Ebola vaccine.

Experts Reveal Ebola Vaccine Status and Potential

The National Institute of Allergy and Infectious Diseases began a first-in-human trial of an experimental live, attenuated Zika virus vaccine.

Zika Vaccine Clinical Trial Begins

The acquisition is expected to support Emergent BioSolutions’ focus on public health threats and emerging infectious disease.